RxDoctor Payments Data

Walter Lajara-Nanson, MD

Neurology · Great Falls, MTNPI 1528050283

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (41.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by AbbVie at 41.6% of the total. Reporting peaked in 2019 at $1,919 and has fallen 73.9% since, to $501 in 2025.

$5,522in general payments, 2019–2025

Across 87 payments — averaging $63.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$2K
  • Merz Pharmaceuticals, LLC$382
  • TG Therapeutics, Inc.$161
  • Sanofi$90
  • Teva Pharmaceuticals USA, Inc.$84
  • plus $473 from 15 others

What the payments were for

  • Speaking & faculty fees$1,75032%
  • Travel & lodging$1,37425%
  • Food & beverage$2,31342%
  • Education$852%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,522 in reported general payments places this provider in the 75th percentile of 48 neurology providers in Montana.

See all neurology providers in Montana

Medicare billing

Part B allowed, 2024
$108,792
Medicare patients
473
Services billed
1,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab28$251,588
NuplazidPimavanserin Tartrate26$126,681
IngrezzaValbenazine Tosylate11$85,378
RytaryCarbidopa/Levodopa77$74,505
GocovriAmantadine Hcl23$56,533
NuedextaDextromethorphan Hbr/Quinidine29$46,008
Tetrabenazine16$16,904
Dalfampridine ErDalfampridine36$11,190
Ajovy AutoinjectorFremanezumab-Vfrm15$10,160
Lacosamide134$9,899
Aimovig AutoinjectorErenumab-Aooe13$9,331
Emgality PenGalcanezumab-Gnlm12$8,429
TrintellixVortioxetine Hydrobromide17$8,134
Selegiline Hcl64$8,110
Rivastigmine35$6,533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$53$126,68126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 48 neurology providers in Montana.

Other neurology in Great Falls

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →